Cassava Sciences Inc (SAVA) Stock Price, Quote & News

Company Profile

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company w...

Industry: Biotechnology

Sector: Healthcare

Phone: 512-501-2444

Website: www.cassavasciences.com

Address:

6801 N. Capital of Texas Highway, Suite 300 Building 1, Austin, United States

BambooC Aug. 27 at 2:11 PM

$SAVA conference presenting? 👀👀

0 · Reply

mhaven2020 Aug. 27 at 1:40 PM

$SAVA hello there! The party is just around the corner!

1 · Reply

EddieGene Aug. 27 at 1:03 PM

$SAVA let’s go 🚀🚀

0 · Reply

CharlieeMungerTWITS Aug. 26 at 1:03 PM

$CGTX <~~~ partner incoming massive market. $SAVA $OTLK

1 · Reply

StockLust Aug. 26 at 6:26 AM

$SAVA who was that lady that was leading the charge of the SAVA bagholders? I remember her posting almost every day last year but I dont remember her name. Is she still here?

1 · Reply

WallStreetBuyDip Aug. 26 at 5:47 AM

My only strategy since 2019 has been to buy when H% is low. Nothing else. Keep it simple and consistent. The results prove again and again why I‘ll only stick with this strategy Will trade $SAVA like how I did for others

1 · Reply

PSM_EmpowerTrading Aug. 26 at 2:46 AM

🌞🌞watchlist part 1 ✅️ $OPAD low 4 support, if above 4.50, have potential to 5/5.20, high 5.20, up over 420% from swing 🚀🚀CONGRATS if you got in during swing accumulation phase before/low 1 before the breakout , haven't seen such a monster run since $SAVA or $CODX during covid pandemic ✅️ $OPEN multi day runner, current support mid 4.50, if above 4.75, have potential to 5, CONGRATS if you got in below/low 2 during swing accumulation phase, high 5.85 today, up 192% from swing alert 🚀🚀 ✅️ $TLRY 1.30 support, if above 1.50, have potential to 1.75/.85, slow but steady climbing up 33% from swing alert posted low 1.10, Jefferies analyst Kaumil Gajrawala buy rating price target $2, CONGRATS if you got in during swing accumulation phase below/low 1.10 🚨🚨 The above tickers are not ideal for swing accumulation at current price 🎯 🎯 Ideal long stop loss if current support 🚫🚫 Avoid chasing long into strength near resistance 🎯🎯 Goal is GR🤑🤑N not GR🥵🥵D

1 · Reply

CharlieeMungerTWITS Aug. 25 at 7:54 PM

$CGTX $SAVA I was in Sava back when it ran to $60++ in a week for Alzheimer’s drug. CGTX has far superior prospects given their stat sig and low float. Lock in.

2 · Reply

PeterLynch777 Aug. 25 at 7:42 PM

$SAVA Back in. https://www.cassavasciences.com/node/17601/pdf

0 · Reply

CharlieeMungerTWITS Aug. 25 at 7:03 PM

$CGTX $SAVA SAVA ran to $100 with much less. “With strong FDA alignment, promising Alzheimer’s data, and a low share float, CGTX has the explosive upside potential to run into the $50 range—unlike SAVA, weighed down by regulatory baggage.” $OPEN $OTLK

1 · Reply

Cassava Reports Q2 2025 Financials Results and Provides Business Update

Aug 7, 2025, 7:30 AM EDT - 20 days ago

Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer

Aug 4, 2025, 7:30 AM EDT - 23 days ago

Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy

Jun 30, 2025, 7:00 AM EDT - 2 months ago

Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting

May 1, 2025, 7:30 AM EDT - 4 months ago

Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC

Apr 21, 2025, 4:30 PM EDT - 4 months ago

Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development

Mar 26, 2025, 3:49 PM EDT - 5 months ago

Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug

Mar 25, 2025, 10:42 AM EDT - 5 months ago

Cassava Sciences Discontinues Developing Simufilam For Alzheimer's After Another Phase 3 Trial Flop

Mar 25, 2025, 8:05 AM EDT - 5 months ago

Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data

Mar 3, 2025, 7:30 AM EST - 6 months ago

Cassava Sciences Reports 2024 Financial Results and Provides Business Update

Feb 9, 2025, 10:45 AM EST - 7 months ago

Lead Plaintiff Deadline on February 10, 2025 for SAVA Investors - Kessler Topaz Meltzer & Check, LLP Encourages Investors with Losses to Contact the Firm

Feb 7, 2025, 12:08 PM EST - 7 months ago

SAVA Deadline: Rosen Law Firm Urges Cassava Sciences, Inc. (NASDAQ: SAVA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Feb 3, 2025, 5:45 AM EST - 7 months ago

Shareholders of Cassava Sciences, Inc. Should Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA

Jan 23, 2025, 2:47 PM EST - 7 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Jan 7, 2025, 4:30 PM EST - 8 months ago

Cassava Sciences Provides a Business Update

Dec 23, 2024, 5:45 AM EST - 8 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA

Dec 18, 2024, 10:53 AM EST - 9 months ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Dec 13, 2024, 1:16 PM EST - 9 months ago

Rosen Law Firm Urges Cassava Sciences, Inc. (NASDAQ: SAVA) Stockholders with Large Losses in Excess of $100K to Contact the Firm for Information About Their Rights

Dec 10, 2024, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Cassava Sciences, Inc. (SAVA) Shareholders to Inquire about Securities Investigation

Dec 9, 2024, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Cassava Sciences, Inc. (SAVA) And Encourages Shareholders to Connect

BambooC Aug. 27 at 2:11 PM

$SAVA conference presenting? 👀👀

0 · Reply

mhaven2020 Aug. 27 at 1:40 PM

$SAVA hello there! The party is just around the corner!

1 · Reply

EddieGene Aug. 27 at 1:03 PM

$SAVA let’s go 🚀🚀

0 · Reply

CharlieeMungerTWITS Aug. 26 at 1:03 PM

$CGTX <~~~ partner incoming massive market. $SAVA $OTLK

1 · Reply

StockLust Aug. 26 at 6:26 AM

$SAVA who was that lady that was leading the charge of the SAVA bagholders? I remember her posting almost every day last year but I dont remember her name. Is she still here?

1 · Reply

WallStreetBuyDip Aug. 26 at 5:47 AM

1 · Reply

PSM_EmpowerTrading Aug. 26 at 2:46 AM

1 · Reply

CharlieeMungerTWITS Aug. 25 at 7:54 PM

$CGTX $SAVA I was in Sava back when it ran to $60++ in a week for Alzheimer’s drug. CGTX has far superior prospects given their stat sig and low float. Lock in.

2 · Reply

PeterLynch777 Aug. 25 at 7:42 PM

$SAVA Back in. https://www.cassavasciences.com/node/17601/pdf

0 · Reply

CharlieeMungerTWITS Aug. 25 at 7:03 PM

1 · Reply

CharlieeMungerTWITS Aug. 25 at 7:02 PM

$CGTX $SAVA who remembers SAVA run from $10 to 100 within 2 weeks? Cognition Therapeutics (CGTX) represents a unique investment opportunity compared to Cassava Sciences (SAVA) because it combines clean regulatory momentum, strong Phase 2 data, and a very low float of shares—creating the perfect setup for outsized price moves. With FDA alignment on its Phase 3 path and encouraging trial results in both Alzheimer’s and Dementia with Lewy Bodies, CGTX stands on solid scientific and regulatory ground, unlike SAVA which remains weighed down by ongoing investigations and credibility issues. The scarcity of available CGTX shares in the market magnifies demand-driven rallies, meaning any positive catalyst—trial updates, partnerships, or buyout speculation—can drive exponential upside. This dynamic positions CGTX as a realistic contender for a sharp rerating into the $50 range, offering investors asymmetric reward relative to SAVA’s high-risk, low-confidence profile.

2 · Reply

wrengler4 Aug. 25 at 9:44 AM

$NTLA ask Barry that at $SRPT or even at $SAVA He has a different take on that ! Lol

0 · Reply

History101 Aug. 25 at 3:33 AM

$CGTX $DRUG went from $1.08 on Oct 11, 2025 to $79 on Oct 18, 2025 and was above $50 for several weeks after. $SAVA went from $4 to $140 in less than 1 year.

0 · Reply